Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 4Phase NA 3Phase 3 3Phase 1/2 2

Status

Withdrawn 3Terminated 3Completed 2Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 92Breast Neoplasms 85Neoplasms 79Prostatic Neoplasms 50Lung Neoplasms 43Neoplasm Metastasis 40Colorectal Neoplasms 37Leukemia, Myeloid, Acute 32Pain 27Head and Neck Neoplasms 25Colonic Neoplasms 25Multiple Myeloma 24Ovarian Neoplasms 23Lymphoma 23Carcinoma, Hepatocellular 23Pancreatic Neoplasms 22Lymphoma, Follicular 21Melanoma 20Leukemia 20Rectal Neoplasms 19Lymphoma, Non-Hodgkin 19Urinary Bladder Neoplasms 17Recurrence 17Stomach Neoplasms 15Lymphoma, Large B-Cell, Diffuse 15Leukemia, Lymphocytic, Chronic, B-Cell 15Squamous Cell Carcinoma of Head and Neck 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leiomyoma 13Brain Neoplasms 13

Interventions

valrubicin 1Standard of Care 1Mitomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Terminated × Urologic Neoplasms × Clear all
NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT01200992 2017-08-24

EMBARC-RF

Bioniche Life Sciences Inc.

Phase 3 Terminated
84 enrolled 7 charts
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Mycobacterium Infections, Neoplasm Recurrence, Local, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT00384891 2014-10-07

Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer

Medical Enterprises Europe B.V.

Phase 3 Terminated
190 enrolled
Genitourinary

Hyperthermia, Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Neoplasms by Site, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡